Switch theme
Sign up to access all valuation multiples
Pacific Shuanglin Bio-pharmacy Co Ltd is engaged in the research, development, production, and marketing of blood products.
1993
2.8K+
LTM Revenue $394M
LTM EBITDA $141M
$2.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pacific Shuanglin has a last 12-month revenue (LTM) of $394M and a last 12-month EBITDA of $141M.
In the most recent fiscal year, Pacific Shuanglin achieved revenue of $368M and an EBITDA of $136M.
Pacific Shuanglin expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pacific Shuanglin valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $394M | XXX | $368M | XXX | XXX | XXX |
| Gross Profit | $196M | XXX | $181M | XXX | XXX | XXX |
| Gross Margin | 50% | XXX | 49% | XXX | XXX | XXX |
| EBITDA | $141M | XXX | $136M | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 37% | XXX | XXX | XXX |
| EBIT | $124M | XXX | $112M | XXX | XXX | XXX |
| EBIT Margin | 31% | XXX | 30% | XXX | XXX | XXX |
| Net Profit | $111M | XXX | $103M | XXX | XXX | XXX |
| Net Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Pacific Shuanglin's stock price is CNY 22 (or $3).
Pacific Shuanglin has current market cap of CNY 16.2B (or $2.2B), and EV of CNY 15.4B (or $2.1B).
See Pacific Shuanglin trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.1B | $2.2B | XXX | XXX | XXX | XXX | $0.15 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Pacific Shuanglin has market cap of $2.2B and EV of $2.1B.
Pacific Shuanglin's trades at 5.8x EV/Revenue multiple, and 15.7x EV/EBITDA.
Equity research analysts estimate Pacific Shuanglin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pacific Shuanglin has a P/E ratio of 20.2x.
See valuation multiples for Pacific Shuanglin and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV/Revenue | 5.4x | XXX | 5.8x | XXX | XXX | XXX |
| EV/EBITDA | 15.2x | XXX | 15.7x | XXX | XXX | XXX |
| EV/EBIT | 17.3x | XXX | 19.2x | XXX | XXX | XXX |
| EV/Gross Profit | 10.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 20.2x | XXX | 21.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -77.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPacific Shuanglin's last 12 month revenue growth is 15%
Pacific Shuanglin's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $25K for the same period.
Pacific Shuanglin's rule of 40 is 52% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pacific Shuanglin's rule of X is 74% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pacific Shuanglin and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 37% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | 16% | XXX | XXX | XXX |
| Rule of 40 | 52% | XXX | 52% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 74% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $25K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pacific Shuanglin acquired XXX companies to date.
Last acquisition by Pacific Shuanglin was XXXXXXXX, XXXXX XXXXX XXXXXX . Pacific Shuanglin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Pacific Shuanglin founded? | Pacific Shuanglin was founded in 1993. |
| Where is Pacific Shuanglin headquartered? | Pacific Shuanglin is headquartered in China. |
| How many employees does Pacific Shuanglin have? | As of today, Pacific Shuanglin has 2.8K+ employees. |
| Is Pacific Shuanglin publicy listed? | Yes, Pacific Shuanglin is a public company listed on SHE. |
| What is the stock symbol of Pacific Shuanglin? | Pacific Shuanglin trades under 000403 ticker. |
| When did Pacific Shuanglin go public? | Pacific Shuanglin went public in 1996. |
| Who are competitors of Pacific Shuanglin? | Similar companies to Pacific Shuanglin include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Pacific Shuanglin? | Pacific Shuanglin's current market cap is $2.2B |
| What is the current revenue of Pacific Shuanglin? | Pacific Shuanglin's last 12 months revenue is $394M. |
| What is the current revenue growth of Pacific Shuanglin? | Pacific Shuanglin revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Pacific Shuanglin? | Current revenue multiple of Pacific Shuanglin is 5.4x. |
| Is Pacific Shuanglin profitable? | Yes, Pacific Shuanglin is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Pacific Shuanglin? | Pacific Shuanglin's last 12 months EBITDA is $141M. |
| What is Pacific Shuanglin's EBITDA margin? | Pacific Shuanglin's last 12 months EBITDA margin is 36%. |
| What is the current EV/EBITDA multiple of Pacific Shuanglin? | Current EBITDA multiple of Pacific Shuanglin is 15.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
